Becton Dickinson (BDX) AI Stock Analysis

• Market Cap: $55.38B
• Dividend Yield: 2.35%
• Average Volume (3M): 2.50M
• Price to Earnings (P/E): 33.4
• Beta (1Y): 0.38
• Revenue Growth: 8.23%
• EPS Growth: -2.04%
• Country: US
• Employees: 70,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.96
• Shares Outstanding: 285,418,550
• 10 Day Avg. Volume: 1,831,928
• 30 Day Avg. Volume: 2,503,490
• PEG Ratio: -47.00
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 2.46
• P/FCF Ratio: 20.09
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 3.34
• Enterprise Value/Gross Profit: 7.35
• Enterprise Value/Ebitda: 14.71
• 1Y Price Target: $193.71
• Price Target Upside: 0.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 14.86
• Revenue Forecast (FY): $22.47B

• Rating: 64 Neutral
• Price Target: $194.00 ▲(1.14% Upside)

Becton Dickinson's overall stock score reflects strong financial performance and strategic initiatives that support future growth. However, technical indicators suggest a bearish trend, and valuation metrics indicate the stock is relatively expensive. Challenges in key markets and segments, as highlighted in the earnings call, also weigh on the score.

Positive Factors

Operational Efficiency

The company's focus on operational efficiency through the BD Excellence model has led to significant margin expansion, indicating strong cost management and profitability improvements, which are crucial for long-term financial health.

Strategic Initiatives

Strategic initiatives like cost reduction programs and leadership changes are expected to enhance operational performance and drive growth, positioning the company for sustained success in the competitive medical technology sector.

Regulatory Approvals

Regulatory approvals for new products expand BDX's market opportunities and enhance its competitive position, supporting long-term revenue growth and innovation in the medical technology industry.

Negative Factors

Vaccine Demand Decline

A significant decline in vaccine demand poses a challenge to revenue growth, particularly affecting the Pharm Systems segment, which may impact the company's overall financial performance in the medium term.

China Market Challenges

Regulatory and market challenges in China are expected to negatively impact growth, highlighting the risks associated with geopolitical factors and reliance on international markets for expansion.

Alaris Headwinds

The anticipated slowdown in Alaris capital installations presents a significant growth headwind, affecting the company's ability to maintain momentum in this key segment, which could impact future revenue streams.

Becton Dickinson Business Overview & Revenue Model

Company Description

Becton Dickinson (BDX) is a global medical technology company that focuses on advancing the world of health by providing innovative solutions that help healthcare professionals improve patient outcomes. Established in 1897, BDX operates in three primary sectors: BD Medical, BD Life Sciences, and BD Interventional. The company's core products include needles, syringes, and infusion systems in the BD Medical segment, diagnostic instruments and reagents in the BD Life Sciences segment, and various interventional devices in the BD Interventional segment. BDX is dedicated to enhancing the safety, quality, and efficiency of healthcare delivery worldwide.

How the Company Makes Money

Becton Dickinson generates revenue through the sale of a diverse range of medical devices, equipment, and diagnostic solutions across its three main sectors. The BD Medical segment is a significant revenue source, contributing through products like syringes, needles, and infusion systems used widely in hospitals and clinics. BD Life Sciences generates revenue from diagnostic instruments, reagents, and microbiology products, which are essential for laboratory testing and disease management. The BD Interventional segment includes products for surgical and minimally invasive procedures, further enhancing the company's revenue. Additionally, BDX benefits from partnerships with healthcare providers, research institutions, and technology companies that facilitate the development and distribution of its products, enhancing its market presence and driving sales. The company's focus on innovation and expanding its product portfolio also plays a crucial role in maintaining a steady revenue stream.

Becton Dickinson Financial Statement Overview

Summary

Becton Dickinson demonstrates robust financial performance with consistent revenue growth and solid profitability margins. The company has improved its leverage position, although return on equity has seen a slight decline. Cash flow generation remains strong, but there is room for improvement in cash flow conversion. Overall, the company is in a stable financial position with positive growth prospects.

Income Statement

Becton Dickinson shows a solid revenue growth rate of 2.12% in the TTM, with a stable gross profit margin of 45.44%. However, the net profit margin has slightly decreased to 7.68% from 8.45% in the previous year. The EBIT and EBITDA margins remain healthy at 11.42% and 22.70%, respectively, indicating strong operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.34 in the TTM, indicating better leverage management compared to the previous year. Return on equity is at 5.11%, showing a slight decline, which could be a concern for investors. The equity ratio stands at 45.89%, reflecting a stable financial position.

Cash Flow

Free cash flow growth is positive at 4.71% in the TTM, which is a good sign. The operating cash flow to net income ratio is strong at 3.04, suggesting efficient cash generation. However, the free cash flow to net income ratio has slightly decreased to 0.78, indicating a need for improvement in cash flow conversion.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	21.84B	―	21.84B	20.18B	19.37B	18.87B
Gross Profit	9.92B	―	9.92B	9.13B	8.17B	8.48B
EBITDA	4.96B	―	4.96B	4.82B	4.40B	4.41B
Net Income	1.68B	―	1.68B	1.71B	1.48B	1.78B
Balance Sheet
Total Assets	55.33B	―	55.33B	57.29B	52.78B	52.93B
Cash, Cash Equivalents and Short-Term Investments	859.00M	―	859.00M	2.16B	1.42B	1.01B
Total Debt	19.18B	―	19.18B	20.11B	15.88B	16.07B
Total Liabilities	29.94B	―	29.94B	31.40B	26.98B	27.65B
Stockholders Equity	25.39B	―	25.39B	25.89B	25.80B	25.28B
Cash Flow
Free Cash Flow	2.67B	―	2.67B	3.07B	2.12B	1.66B
Operating Cash Flow	3.43B	―	3.43B	3.80B	2.99B	2.63B
Investing Cash Flow	-818.00M	―	-818.00M	-5.51B	-716.00M	-3.23B
Financing Cash Flow	-3.62B	―	-3.62B	2.09B	-1.96B	-591.00M

Becton Dickinson Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 191.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Positive. The current price of 191.82 is above the 20-day moving average (MA) of 187.99, above the 50-day MA of 187.46, and above the 200-day MA of 190.64, indicating a bullish trend. The MACD of 2.16 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 62.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDX.

Becton Dickinson Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ISRG	78 Outperform	$203.30B	75.91	16.90%	―	22.18%	21.37%
RMD	71 Outperform	$37.34B	26.18	25.41%	0.88%	9.36%	29.56%
HOLX	69 Neutral	$16.71B	30.19	11.12%	―	1.74%	-25.29%
WST	68 Neutral	$19.95B	41.07	16.94%	0.31%	4.90%	-0.26%
BDX	64 Neutral	$55.38B	33.36	6.54%	2.35%	8.23%	-2.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	40 Neutral	$9.63B	―	-4.70%	2.73%	-21.20%	-325.40%

Becton Dickinson Corporate Events

Becton, Dickinson and Co Reports Strong Fiscal 2025 Results

Becton, Dickinson and Co (BD) is a global leader in medical technology, specializing in advancing healthcare through innovative solutions in diagnostics, medical discovery, and care delivery. The company operates across various sectors, including BD Medical, BD Life Sciences, and BD Interventional.

BD’s Earnings Call: Strong Growth Amid Challenges

Becton, Dickinson and Co. (BD) recently held its earnings call, revealing a generally positive sentiment with strong revenue and earnings growth. The company highlighted its high-performing segments, operational efficiencies, and strategic initiatives as key drivers for future growth. However, challenges such as declining vaccine demand, market dynamics in China, and headwinds from Alaris were also acknowledged as significant hurdles.

BD’s New Vascular Access Study: What Investors Need to Know

Study Overview: The clinical study titled ‘BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study’ is being conducted by Becton, Dickinson and Co. The primary goal is to collect safety and performance data on the BD Prevue II system, which will support regional registrations and identify any unforeseen risks. This study is significant as it aims to enhance the safety and efficacy of peripheral vascular access procedures.

BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access

Study Overview: Becton, Dickinson and Co (BDX) is conducting a clinical study titled ‘BD SiteRite(TM) 9 Ultrasound System – Clinical Study’. The study aims to gather safety and performance data on the BD SiteRite 9 System, crucial for supporting regional registrations like the EU MDR and identifying any unforeseen risks.

Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications

Study Overview: Becton, Dickinson and Company (BDX) is conducting a clinical validation study titled Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product. The study aims to validate the efficacy of BACTEC™ Plus Aerobic/F Culture Vials in diagnosing sepsis, a critical condition. This multi-center, randomized study holds significance as it could enhance diagnostic accuracy and patient outcomes in sepsis management.

BDX’s Innovative Study on BD PosiFlush™ SafeScrub: Market Insights

Study Overview: Becton, Dickinson and Co (BDX) is conducting an investigational study titled An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices. The study aims to assess the safety and effectiveness of the BD PosiFlush™ SafeScrub device in preventing catheter-related bloodstream infections (CRBSI), a significant concern in healthcare settings.

Becton Dickinson Announces CFO Transition Plan

On October 15, 2025, BD announced a CFO transition plan as Chris DelOrefice will depart on December 5, 2025, with Vitor Roque stepping in as interim CFO. The company also reported preliminary unaudited revenue results for the fourth quarter and full year fiscal 2025, showing significant growth across various segments despite challenges in the macro environment. BD continues to focus on strategic goals and investments to drive growth and margin momentum.

The most recent analyst rating on (BDX) stock is a Hold with a $203.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Becton Dickinson Secures $2.75 Billion Credit Facility

On September 16, 2025, Becton Dickinson and its subsidiary BD Euro Finance entered into a third amended and restated credit agreement with Citibank and other lenders, providing a $2.75 billion senior unsecured revolving credit facility. This agreement, which can be extended up to $3.25 billion, will support the company’s general corporate purposes and includes specific financial covenants and conditions, potentially impacting the company’s financial strategy and flexibility.

The most recent analyst rating on (BDX) stock is a Buy with a $206.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

BDX Advances Safety with New Clinical Study on PosiFlush™ SafeScrub

Study Overview: Becton, Dickinson and Company (BDX) is conducting an investigational study titled ‘An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices.’ The study aims to assess the safety and performance of the BD PosiFlush™ SafeScrub, with the data intended for regulatory submission in the EU, highlighting its significance in enhancing medical device safety.

BD PosiFlush™ SafeScrub Study: A Potential Game-Changer for Medical Device Safety

The investigational study titled ‘An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices’ aims to assess the safety and performance of the BD PosiFlush™ SafeScrub. Conducted by Becton, Dickinson and Company, the study seeks to generate clinical data for regulatory submission in the EU, highlighting its significance in enhancing medical device safety and efficacy.